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Abstract
Objective: To demonstrate that RC6 exerts an anticancer effect on MCF-7 
breast cancer cells.
Materials and Methods: MCF-7 breast cancer cells were treated with RC6. 
The survival rate was determined by XTT assay. Apoptosis was observed 
based on nuclear staining and FACS analysis. Caspase activation was 
determined by substrate cleavage assay.
Results: RC6 is able to inhibit the cell growth of MCF-7 cells (breast cancer) 
but not BHK-21 cells (fibroblast). The survival rate of MCF-7 cells is less 
than 50% at day 3 after RC6 treatment. Nuclear staining and FACS analysis 
demonstrated that the RC6-induced cytotoxicity of MCF-7 cells occurred 
via the apoptosis pathway. In addition, caspase activation was found to 
occur because caspase-3-like activity was present in the RC6-treated MCF-7 
cells. However, caspase-8 and caspase-9 were not activated in the RC6-
treated MCF-7 cells.
Conclusion: RC6 is able to induce caspase-3 like activity and this exert an 
anticancer effect on MCF-7 cells. [Tzu Chi Med J 2010;22(4):189–194]
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1. Introduction
Ribonucleases have been shown to have anticancer 
effects [1,2], and onconase and RC-RNase belong 
to the ribonuclease family. Onconase purified from 
Rana pipiens is able to inhibit the cell growth of many 
tumors [3,4]. Similarly, RC-RNase purified from Rana 
catesbeiana also inhibits the cell growth of tumors 
[5,6]. Although the mechanism(s) of onconase-induced/
RC-RNase-induced cytotoxicity are still unclear, it 
should be noted that onconase has been used as an 
anticancer drug in a number of American clinical trials 
[7,8]. RC6 can be purified from bull frog and its 
amino acid sequence is similar to that of onconase 
and RC-RNase [9]. Therefore, it seems likely that RC6 
will have an anticancer effect that is similar to onco-
nase and RC-RNase.
MCF-7 cells belong to estrogen receptor (ER)-positive 
breast cancer cells [10,11]. In the present study, MCF-7 
cells were used to study if cell growth was inhibited 
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and caspases were activated after RC6 treatment. 
Previous studies have shown that cell death is di-
vided into apoptosis and necrosis depending on the 
status of the cell [12,13]. Many studies have also in-
dicated that dead cells created via the apoptosis 
pathway are removed by phagocytes [14,15] and that 
this process has fewer side effects than when cell 
death occurs via the necrosis pathway.
Previous studies have indicated that apoptosis 
can be induced via caspase-dependent or caspase-
independent pathways [16,17]. Substrate cleavage 
assays can be used to determined caspase activities 
[5,18].
This study investigated whether RC6 has a cytotoxic 
effect on MCF-7 cells and whether side effects occur 
via the apoptosis or necrosis pathway. It was found 
that RC6 exerts a time-dependent cytotoxicity on 
MCF-7 cells and that RC6 does not induce a similar 
effect in fibroblasts. DNA fragmentation, condensation 
and the presence of sub-G1 phase cells after treat-
ment with RC6 indicated the induction of apoptosis in 
MCF-7 cells. Under these circumstances, caspase-3-
like activity could be detected in RC6-treated MCF-7 
cells, but not caspase-8 and caspase-9 activity. In 
summary, RC6 exerted an anticancer effect on MCF-7 
breast cancer cells through a caspase-dependent apop-
tosis pathway and the results suggest that RC6 may 
have potential in cancer treatment.
2. Materials and methods
2.1. Reagents and cell culture
RC6 was purified from bull frog using a previously 
published method [9]. Ac-LEHD-pNA (acetyl-Leu-Glu-
His-Asp-p-nitroanilide: caspse-9 substrate), Ac-DEVD-
pNA (Acetyl-Asp-Glu-Val-Asp-p-nitroanilide: caspase-3 
like substrate), and Ac-IETD-pNA (acetyl-Ile-Glu-Thr-
Asp-p-nitroanilide: caspase-8 substrate) were pur-
chased from AnaSpec Inc. (Fremont, CA, USA). The 
XTT assay kit was obtained from Roche (Basel, 
Switzerland). Human breast carcinoma cells (MCF-7), 
human fibroblasts (HS68 and WI38) and mouse fi-
broblast (BHK-21) were purchased from the American 
Type Culture Collection (Manassas, VA, USA) and cul-
tured in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Gibco, Grand Island, NY, USA) supplemented with 
10% heat-inactivated fetal bovine serum (Hyclone 
Laboratories, Logan, UT, USA), 2 mM L-glutamine 
(Gibco), 100 IU/mL penicillin/streptomycin (Gibco), and 
0.1 mM non-essential amino acids (Gibco). Human 
mammary epithelial cells (MCF-10A) were a gift from 
Dr. Yung-Luen Yu (from the Center for Molecular 
Medicine, China Medical University Hospital) and cul-
tured in DMEM/F12 (Gibco) supplemented with 5% 
horse serum, 1% penicillin/streptomycin, 10 μg/mL 
bovine pancreatic insulin, 20 ng/mL epidermal growth 
factor and 0.5 μg/mL hydrocortisone.
2.2. Cell survival assay
Cell survival was measured using an XTT {sodium 
3’-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-
methoxy-6-nitro) benzene sulfonic acid hydrate} kit 
that determines mitochondrial dehydrogenase activity. 
In brief, 5 × 103 cells were grown in each well of a 96-
well plate. On the second day, the cells were treated 
with RC6 (20 μg/mL). XTT assays were carried out 
everyday thereafter for 4 days according to the manu-
facturer’s instructions. The absorbance at 492 nm and 
620 nm were determined using a multi-well ELISA 
reader (Molecular Devices Inc., Sunnyvale, CA, USA).
2.3. Nuclear staining
DNA condensation and fragmentation can be ob-
served during apoptosis and these were assessed by 
nuclear staining and FACS analysis. Nuclear staining 
was performed using Hoechst 33342. The cells were 
treated with 10 μg/mL Hoechst 33342 for 10 min-
utes, and then DNA condensation and fragmentation 
were observed by fluorescence microscopy (excita-
tion, 352 nm; emission, 450 nm).
2.4. FACS analysis
Sub-G1 phase cells occur during apoptosis and can 
be detected by FACS analysis. In brief, cells were 
fixed with 70% alcohol overnight. The next day, the 
cells were treated with 50 mg/mL propidium iodide, 
100 mg/mL RNase A and 0.1% Triton X-100 for 40 
minutes. After washing with phosphate buffered sa-
line, the cells in sub-G1 phase were assayed using a 
FACS machine (CyFlow SL and FloMax; Partec GmbH, 
Görlitz, Germany).
2.5. Caspase activity assay
In order to analyze the activity of various caspases, 
cells were lysed with lysis buffer (50 mM Tris-HCl, 
120 mM NaCl, 1 mM EDTA, 1% NP-40, pH 7.5) in the 
presence of protease inhibitors. The cell pellets were 
discarded after centrifugation at 15,000g for 30 
minutes at 4°C. Caspase activity was assessed in a 
working reaction containing 40 μL cell lysate (80 μg 
total protein), 158 μL reaction buffer (20% glycerol, 
0.5 mM EDTA, 5 mM dithiothreitol, 100 mM HEPES, 
pH 7.5), and 2 μL fluorogenic substrate, either Ac-
LEHD-pNA or Ac-DEVD-pNA or Ac-IETD-pNA (100 μM 
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final concentration); the reaction was incubated at 
37°C for 6 hours. Cleavage of the fluorogenic sub-
strate released p-nitroanilide, which was measured 
at 405 nm in an ultra-microplate reader (BioTek, 
Winooski, VT, USA). The fold increase in caspase ac-
tivity was calculated using the following formula: 
(A405sample − A405control)/A405control.
2.6. Statistical analysis
The results are presented as mean ± standard devia-
tion and analyzed using Student’s t test. A value of 
p < 0.01 was considered statistically significant.
3. Results
3.1. RC6 induced cell cytotoxicity in 
MCF-7 breast cancer cells
Initially, it was found that RC6 was able to induce 
cytotoxicity in MCF-7 cells and that this effect was 
dose-dependent (Fig. 1A). RC6 in the range of 20–
200 μg/mL was able to effectively inhibit the cell 
growth of MCF-7 cells, but there was no significant 
difference between treatment with 20 μg/mL RC6 
and 200 μg/mL RC6. As a result, we used 20 μg/mL 
RC6 throughout this study for cell treatment. To com-
pare RC6-induced cytotoxicty between breast cancer 
cells and normal cells, MCF-7, BHK-21, MCF-10A, WI38 
and HS68 cells were treated with RC6 (20 μg/mL) for 
4 days (Fig. 1B). The results indicated that RC6 was 
able to induce significant cytotoxicity in MCF-7 cells. 
However, no obvious cytotoxicity was induced in 
BHK-21, MCF-10A, WI38 or HS68 cells. Therefore, we 
suggest that RC6 exerts a specific anticancer effect 
against MCF-7 cells.
3.2. RC6 induced cell death in MCF-7 cells 
through apoptosis pathway
As shown in Fig. 1, RC6 induced cytotoxicity in MCF-7 
cells. Therefore, whether RC6 induces cytotoxicity 
through the apoptosis or the necrosis pathway was 
determined next. Many studies have shown that DNA 
condensation and fragmentation are observed dur-
ing apoptosis [19,20]. In this study, nuclear staining 
was performed using Hoechst 33342 and it was 
found that, compared with the control cells (Fig. 2A), 
DNA condensation and fragmentation were present 
in the RC6-treated cells (Fig. 2B). About 35% of RC6-
treated cells showed nuclear fragmentation and con-
densation. Previously, PARP cleavage was shown to 
occur during apoptosis [11]. Western blot analysis at 
day 3 showed that PARP was cleaved and reduced in 
size from 116 kD to 89 kD when MCF-7 cells were 
treated with RC6 (Fig. 2C). These findings support the 
hypothesis that RC6-induced cytotoxicity in MCF-7 
cells occurs via the apoptosis pathway.
In addition, the presence of a sub-G1 phase cell 
population is a good indicator of cell death via the 
apoptosis pathway [21,22]. FACS analysis showed 
that sub-G1 phase cells could be found among RC6-
treated cells on day 3 and that the percentage of 
RC6-treated cells in G1 phase was about 27% by FACS 
analysis. These results, when taken together, suggest 
that RC6-induced cytotoxicity in MCF-7 cells occur 
via the apoptosis pathway.
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Fig. 1 — The 4-day survival rates. (A) MCF-7 cells treated with RC6 (0.2–200 mg/mL). (B) MCF-7, BHK-21, MCF-10A, HS68 
and WI38 cells treated with 20 mg/mL RC6. The results were obtained from four independent triplicate experiments and 
are presented as mean ± standard deviation. On comparing RC6-treated MCF-7 with other RC6-treated cells, there were 
significant differences: *p < 0.01.
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3.3. Caspase-3-like activity was activated in 
RC6-treated MCF-7 cells
Caspase-3-like, caspase-8 and caspase-9 activities were 
measured by incubating cell lysate with an appropriate 
fluorogenic substrate, Ac-LEHD-pNA or Ac-DEVD-pNA 
or Ac-IETD-pNA. Caspase-3-like activity increased in 
a time-dependent fashion when MCF-7 cells were 
treated with RC-6 (Fig. 4A). In contrast, no caspase-8 
and caspase-9 activity could be detected in the RC-6-
treated MCF-7 cells (Figs. 4B and 4C). RC-6-treated 
BHK-21 cells were used as the negative control. 
Neither caspase-3-like, caspase-8 or caspase-9 activ-
ity was found in RC6-treated BHK-21 cells. Thus, the 
present study is the first to demonstrate that RC6 is 
able to induce cytotoxicity in MCF-7 cells via the ap-
optosis pathway by activating caspase-3-like activity.
4. Discussion
Many studies have demonstrated that RC and onco-
nase are able to exert an anticancer effect on breast 
tumors [5,11,23,24]. In this study, we are the first to 
show that RC6 also exerts a similar anticancer effect 
on MCF-7 breast cancer cells. Hu et al showed that the 
5-day survival rate of onconase-treated MCF-7 cells 
was 22% [11], and Tang et al showed that the 5-day 
survival rate of RC-RNase-treated MCF-7 cells was 
about 20% [5]. In this study, the 5-day survival rate of 
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Fig. 2 — Nuclear staining and PARP cleavage. (A) MCF-7 cells without RC6 treatment. DNA condensation and fragmenta-
tion cannot be found. (B) MCF-7 cells after RC6 treatment for 3 days. DNA condensation and fragmentation are found. 
(C) PARP was cleaved from 116 kD to 89 kD in the RC6-treated MCF-7 cells. Actin served as the internal control.
Fig. 3 — The cell cycle was determined by FACS analysis. Sub-G1 phase cells were found in MCF-7 cells at day 3 after 
RC6 treatment.
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RC6-treated MCF-7 cells was about 14% (Fig. 1). 
Therefore, we considered that RC6 has a stronger cy-
totoxic effect on MCF-7 cells than either RC-RNase or 
onconase. However, previous studies have indicated 
that onconase is also able to induce obvious cyto-
toxicity in normal fibroblasts [5]. In addition and im-
portantly, onconase has been used as an anticancer 
drug in clinical trials in the U.S. [7,8]. The present 
study showed that RC6 does not induce obvious cy-
totoxicity in normal fibroblasts (Fig. 1). Taking the 
above into account and in comparison with previous 
studies [5,11], the present results (Fig. 1) suggest 
that RC6 has potential as an anticancer treatment.
Cell death has been divided into the apoptosis 
and necrosis pathways [12,13]. DNA condensation, 
fragmentation and the presence of sub-G1 phase 
cells are the major characteristics of apoptosis [19–
22]. These apoptotic characteristics were found when 
MCF-7 cells were treated with RC-6 (Figs. 2 and 3), 
and the present results support the hypothesis that 
RC6 induces apoptosis in MCF-7 cells.
Previous studies have shown that cytotoxic RNases 
are able to induce apoptosis in cancer cells [25–27]. 
Though the mechanism(s) by which cytotoxic RNase-
induced cytotoxicity occurs have remained unclear, 
RC6 is similar to the previously described cytotoxic 
RNases in that it induces apoptosis in cancer cells. 
Previous studies have demonstrated that apoptosis 
may occur through either a caspase-dependent or a 
caspase-independent pathway [16,17]. As shown in 
Fig. 4, caspase-3-like activity was found in RC6-treated 
MCF-7 cells. Our results support the hypothesis that RC6 
induces apoptosis via a caspase-dependent pathway. 
In addition, many studies have shown that caspase-
3/-8-like and caspase-3/-9-like activities are the major 
caspase cascade pathways [28–30]. However, neither 
caspase-8 nor caspase-9 activity was found in RC6-
treated MCF-7 cells (Figs. 4B and 4C). We suggest that 
the RC6-induced caspase cascade may occur through 
an atypical pathway, which is similar to a number of 
previous studies [11,31,32]. Earlier studies have in-
dicated that downregulation of inhibitors of apoptosis 
proteins (IAPs) is able to induce apoptosis via XIAP, 
CIAPs and survivin [33,34]. IAP-induced apoptosis 
via caspase-dependent and caspase-independent 
pathways have been demonstrated [35,36]. Recently, 
a number of studies have shown that IAPs are able to 
activate effector caspases (caspase-3, caspase-7) with-
out the activation of initiator caspases (caspase-8, 
caspase-9) [37–39]. Our study shows that RC6 only 
induces caspase-3-like activity and not caspase-8 and 
caspase-9 activity. Thus, the levels of various IAPs 
(survivin, XIAP and CIAPs) were determined by Western 
blot. However, downregulation of these IAPs was not 
found in RC6-treated MCF-7 cells. We therefore sug-
gest that unknown mechanisms that induce caspase-
3-like activity but bypass caspase-8 and caspase-9 
activation may be responsible, and these unknown 
mechanisms will be investigated in future.
Taken together, this study is the first to demon-
strate that RC6 induces apoptosis in MCF-7 cells via 
the caspase-3-like pathway via a novel route. Our 
studies also suggest that RC6 may be useful for anti-
cancer treatment in the future.
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